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Abstract
Background: To investigate the feasibility, and safety of 125I seed permanent implantation for recurrent head and
neck carcinoma under CT-guidance.
Results: A retrospective study on 14 patients with recurrent head and neck cancers undergone 125I seed
implantation with different seed activities. The post-plan showed that the actuarial D90 of 125I seeds ranged from
90 to 218 Gy (median, 157.5 Gy). The follow-up was 3 to 60 months (median, 13 months). The median local control
was 18 months (95% CI, 6.1-29.9 months), and the 1-, 2-, 3-, and 5- year local controls were 52%, 39%, 39%, and
39%, respectively. The 1-, 2-, 3-, and 5- survival rates were 65%, 39%, 39% and 39%, respectively, with a median
survival time of 20 months (95% CI, 8.7-31.3 months). Of all patients, 28.6% (4/14) died of local recurrence, 7.1% (1/
14) died of metastases, one patient died of hepatocirrhosis, and 8 patients are still alive to the date of data
analysis.
Conclusion: CT-guided 125I seed implantation is feasible and safe as a salvage or palliative treatment for patients
with recurrent head and neck cancers.
Background
Most patients who have ever undergone surgery for
head and neck cancer or those local advanced or regio-
nal recurrence cancer patients received surgery com-
bined with adjuvant external-beam radiotherapy (EBRT)
[1,2]. Management of patients with recurrent head and
neck cancers after surgery, EBRT, and adjuvant che-
motherapy is a challenge for clinical oncologists. Salvage
surgery is often technically feasible after the patients
treated with full doses of EBRT, but the curative poten-
tial of surgery alone is low; further, the morbidity is
high [3]. Redelivery of effective doses of EBRT is diffi-
cult because of the limited tolerance of adjacent normal
tissues. Therefore, there has been a growing interest in
combining salvage surgery with intraoperative interstitial
brachytherapy [4].
Temporary intraoperative interstitial brachytherapy
has its advantage in this aspect, in which a high dose of
radiation is delivered directly to the cancer, while ensur-
ing that a much lower dose is delivered to the adjacent
normal structures [5-7]. The use of high-dose rate
(HDR) and low-dose rate (LDR) brachytherapy in pre-
viously irradiated regions is often safe because the use
of implants ensures the delivery of the dose to very spe-
cific and limited volumes of tissue. A variety of isotopes
are available for use as HDR or LDR temporary intersti-
tial brachytherapy, but the most commonly used isotope
is Iridium-192, Co-60 or Cs-137 et al, especially for
treating recurrent solid cancers [8-10]. However, the use
of those isotopes for intraoperative HDR brachytherapy
requires very complicated shielding [11].
Computed tomography (CT)-guided permanent bra-
chytherapy was initially used for treating liver malignan-
cies [12,13]. This novel technique ensures protracted
cell killing over a period of several months through tar-
geted delivery of high-dose radiation. The advantages of
this technique are as follows: (1) it is minimally invasive,
(2) dose distribution can be accurately predicted, (3)
continuous irradiation increases the likelihood of dama-
ging malignant cells in a vulnerable phase of the cell
cycle, and (4) the incidence rate of acute adverse effects
is low.
We have gained significant experience in using perma-
nent 125I seed implantation for treating recurrent rectal
* Correspondence: doctorwangjunjie@yahoo.com.cn
† Contributed equally
1Department of Radiation Oncology, Peking University Third Hospital, Beijing
100191, PR China
Jiang et al. Radiation Oncology 2010, 5:68
http://www.ro-journal.com/content/5/1/68
© 2010 Jiang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
cancer and spinal metastases [14,15]. The theoretical
benefit of seed permanent implantation as a salvage
treatment is enhanced disease control in the region of
recurrence through precise and continuous LDR irradia-
tion, which, in turn, minimizes injury to the overlying
skin and surrounding neurovascular structures.
In this study, we investigated the efficacy and feasibil-
ity of percutaneous CT-guided 125I seed permanent
implantation for recurrent head and neck cancers and
analyzed the local control, survival and complications of
this modality.
Patients and methods
We conducted a retrospective analysis of 14 patients
(median age, 40 years; range, 19-74 years) who had been
treated for recurrent head and neck cancers with CT-
guided 125I seed permanent implantation at Peking Uni-
versity Third Hospital between Feb 2003 and November
2009. The study population included 9 male and 5
female patients. The criteria for eligibility were as fol-
lows: histologically proven recurrent head and neck can-
cer after surgery and radiotherapy, without any evidence
of distant metastasis; a Karnofsky Performance Status
(KPS) score ≥60; and no severe impairment of kidney,
liver, or bone marrow function. The diameter of recur-
rent tumor was less than 7 cm. All patients had ever
been reviewed by the surgeons and radiation oncolo-
gists, and were considered not suitable for salvage sur-
gery and EBRT again or the patients refused to receive
surgery and EBRT further.
Before the operation, we evaluated the history and
physical condition of all the patients, hematological
and chemical tests, and obtained CT images of the head
and neck and radiographs of the chest. Patient charac-
teristics are shown in Table 1.
Of the 14 patients, 2 had undergone radical surgery
alone, 6 had received EBRT alone, and 6 had undergone
surgery and EBRT. Two patients had undergone surgery
twice and the other two patients had undergone surgery
three times. Among the patients who underwent EBRT,
1, 5, and 6 patients received it 4 times, twice, and once,
respectively. The total dose delivered to PTV ranged
from 48.5 to 250 Gy (median, 70 Gy). Six patients had
been administered chemotherapy (3-13 cycles; median, 4
cycles). Five patients had regional recurrence in the
lymph nodes and 9 patients had recurrence in the pri-
mary lesions.
A detailed CT-aided tumor-volume study was also
performed for all the patients 1-2 weeks before seed
implantation. We obtained transverse images of the tar-
gets at 5-mm intervals. The images were transferred to
a computerized treatment planning system (TPS, Pro-
wess, version 3.02, SSGI, USA). The radiation oncologist
outlined the planning target volume (PTV) on each
transverse image, to which the prescribed D90 (the
doses delivered to 90% of the target volume) was pre-
scribed. The PTV included the gross tumor volume
(GTV) with a 0.5-1 cm margin. A radiation dose of 90-
160 Gy was prescribed to the PTV and calculated
through computerized treatment planning system.
We had previously reported the implant technique
used in this study [14]. Seed implantation was per-
formed in all the 14 patients under local anesthesia in
the CT room. After determining the target volume, 18-
gauge interstitial needles were inserted into the tumor
through the skin surface with PTV under CT supervi-
sion. Most of the 18-gauge needles were placed 1.0 cm
apart in a parallel array in the PTV. Precautions were
taken to avoid puncturing the large vascular and neural
Table 1 Patient characteristics (n = 14)












Stage I 1 7
Stage II 3 21
Stage III 4 29
Stage IV 5 36
Unclear 1 7
Primary tumor
Sinus paranasal 5 36
Nasopharynx carcinoma 3 21
Larynx 2 14.3
Hypopharyngeal carcinoma 1 7
Nasal cavity 1 7
Mandible 1 7
Infratemporal fossa 1 7
Previous surgery 8 57
Previous chemotherapy 6 43





≤50 Gy 2 14
50 ~ 100 Gy 5 36
>100 Gy 5 36
Median dose(Gy) 70(range,50-250)
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structures and the bronchus. The median number of
needles is 14 (range, 5-42). After placing the needles,
125I seeds (Model 6711; Beijing Atom and High Techni-
que Industries Inc., Beijing) were implanted using a
Mick applicator; the seeds were implanted 1.0 cm apart.
All the patients received perioperative prophylactic
antibiotics.
Postoperative dosimetric measurements were routinely
obtained for all the patients. The implant dosimetry was
determined using three-dimensional seed identification,
and axial CT images (slice thickness, 5 mm) of the
implanted area were obtained immediately or 24 h after
seed implantation. The CT-derived postimplant target
volumes were defined to encompass the GTV with a
0.5-1 cm margin. The 125I seeds were identified on the
CT images by using a combination of manual selection
and an automated redundancy check feature available
on the Prowess treatment planning system. We gener-
ated isodose curves for each slice (Fig. 1) and dose-
volume histograms of the target (Fig. 2). The actuarial
median number of the implanted 125I seeds was 48
(range, 21-158). The specific activity of 125I seeds ranged
from 0.40 to 0.80 mCi/seed (median, 0.65 mCi). The
total activity of the implanted seeds ranged from 8.8 to
113.6 mCi (median, 24.9 mCi). The evaluation of post
plan shown the actuarial D90 ranged from 90 to 218 Gy
(median, 157.5 Gy). The seed implanted volume ranged
from 9.1 to 290.4 cm3 (median, 32 cm3).
Tumor response was first evaluated at 4 weeks after
implantation. Subsequent evaluations were performed at
2-3- month interval for the next 2 years and 6-month
interval, thereafter. The disease status was assessed by
physical examinations, liver function tests, and complete
blood and platelet counts. Disease progression was
determined by means of imaging studies, including CT
scans and ultrasonography. The follow-up time was cal-
culated from the date of seed implantation. The median
follow-up period was 13 months (range, 3-60 months).
The complications were scored using the Radiation
Therapy Oncology Group (RTOG)/European Organiza-
tion for Research and Treatment of Cancer (EORCT)
late radiation morbidity score [16].
The survival time was calculated from the date of
implantation to the last date of follow-up or date of
death. In these calculations, deaths due to any reason
were scored as events. Local control was defined as the
lack of tumor progression either in or adjacent to the
implanted volume. Tumor responses were assessed
using CT and ultrasound according to the World Health
Organization (WHO) criteria [17]. The overall local
control and survival times were determined using the




The follow-up period ranged from 3 to 60 months
(median, 12 months). The median local control was 18
months (95% CI, 6.1-29.9 months), and the 1-, 2-, 3-
and 5-year local controls were 52%, 39%, 39%, and 39%,
respectively. Of all patients, 28.6% (4/14) died of local
recurrence, 7.1% (1/14) died of metastases, and 1 died of
hepatocirrhosis 20 months after seed implantation and 8
still survive to the date of this analysis (Fig. 3).
Survival
The median survival time was 20 months (95% CI, 8.7-
31.3 months), and the 1-, 2-, 3- and 5-year survival rates
were 65%, 39%, 39%, and 39%, respectively (Fig. 4).
Complications
One patient had grade one skin reaction, one experi-
enced grade 1 mucosal reaction, and one developed
ulceration with tumor progression after 11 months. We
did not observe blood vessel damage and neuropathy in
the patients.
Discussion
The treatment of patients with recurrent head and neck
cancer in a previously irradiated area is particularly chal-
lenging for both surgery and EBRT. In such circum-
stances, redelivery of EBRT is not possible because of
Figure 1 The isodose curve after seed implantation from CT
scan. The inner red cure represents GTV. The ellipses are iso-dose
lines of 160, 140, 120, 90 Gy from inside, respectively.
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the high radiation dosage previously applied and the tol-
erance of adjacent normal tissue. However, local control
rates of up to 50% and a 5-year survival rate of 20%
have been reported after redelivery of EBRT [18-20].
The use of re-irradiation combined with chemotherapy
for recurrent head and neck carcinomas, after previous
full-dose radiotherapy, has shown encouraging median
survivals [21-23]. However, this approach has sometimes
met some trouble for patients who have ever received
EBRT and worry about the normal tissue damages. The
re-irradiation possibility is small for patients who have
ever received twice EBRT, even IMRT or IGRT.
Surgery combined with intraoperative HDR interstitial
brachytherapy has become a modality of salvage treat-
ment for managing patients with locally advanced or
recurrent head and neck cancer, with a local control
rate of 40-60% and a 5-year survival rate of 14% [24,25].
Salvage surgery or surgery combined with intraoperative
Figure 2 The Dose volume histograms of GTV and spinal cord after seed implantation.
Figure 3 Kaplan-Meier estimates showing local control for all
the patients after 125I seed implantation.
Figure 4 Kaplan-Meier estimates showing overall survival for
all the patients after 125I seed implantation.
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HDR is often technically feasible, but its curative poten-
tial is low, and local failure rate is ≥40% [26].
Intraoperative pulsed-dose-rate (PDR) brachytherapy is
an alternative reirradiation strategy that lowers the risk
of severe morbidity [27]. The use of this technique
resulted in excellent local control rates of up to 80%
with minimal side effects when performed in carefully
selected patients [28]. Intraoperation PDR imposed
some practical limitations, the tumor size and location
of most recurrences inhibited its application. Normal
tissue fibrosis after EBRT can impair bimanual palpation
of recurrent tumors during the needle implantation, the
organ at risk is often in the vicinity of the tumor. The
patient treatment usually lasted several days. Radium-
226 and iridium-192 have been used for T1 and T2
patients with oral cavity and oropharynx carcinomas
and produced excellent control rates and functional
results [29-33]. Vikram et al reported 124 patients with
advanced recurrent head and neck cancer who were
treated using 125I implants [34]; 71% of these patients
showed complete regression, 18% showed >50% regres-
sion, and 11% showed no response. Overall, local con-
trol was achieved in 64% of the patients until their
deaths. Only 9% of the patients survived for 2 years and
5.5% survived for 5 years. Goffinet et al reported using
permanent 125I seed implants as a surgical adjuvant in
the management of patients with advanced recurrent
head and neck cancer; most of the patients in this study
had received prior treatment. Management involved a
salvage operation combined with permanent 125I seed
implants, and a local control rate of 70% had been
achieved [35]. Park et al reported 35 patients with
advanced recurrent squamous cell cancers of the head
and neck that were treated with surgical resection fol-
lowed by adjuvant 125I seed implantation. The 5-year
disease-free survival rate was 41% [36]. The use of con-
comitant intraoperative HDR or LDR brachytherapy has
been shown to enhance actuarial survival and local con-
trol rates, but the occurrence of local complications
have also been reported in 11-56% of cases [37]. Marti-
nez et al reported an overall complication rate of 11%
[37], and Goffinet et al reported an overall complication
rate of approximately 50% [35]. The main complications
were skin ulceration and wound breakdown; however,
carotid rupture, which is a fatal complication, has also
been occasionally reported.
Catheters are inserted during intraoperative HDR or
PDR brachytherapy on the basis of preoperative images
and intraoperative presentation. Planning of intraopera-
tive HDR or PDR brachytherapy has a number of poten-
tial disadvantages: (1) the target volume and shape may
change between the time of pre-plan and real time
implant insertion; (2) the dose calculation is depended
on pre-plan, and did not realized real time and post-
plan in operation or after operation. However, image-
guided seed permanent implantation overcomes these
disadvantages in some selected patients. We observed a
very low rate of complications, one patient had grade
one skin reaction, one experienced grade one mucosal
reaction, and one developed ulceration with tumor pro-
gression after 11 months, and no adverse events were
attributable to seed implantation itself. One patient had
ulceration because of tumor progression after seed
implantation. We did not observe the occurrence of
bone and soft tissue necrosis, carotid rupture, or other
grade 4 or 5 toxicity.
Image-guided HDR brachytherapy for non-small-cell
lung cancer and other malignancies has recently been
reported by other groups [38-41]. This enables the use
of circumscribed high-dose radiotherapy for the tumor
target as well as the safety margin. CT-guided 125I per-
manent seed implantation has the following advantages:
(1) the implantation technique is supervised real timely
on CT scan and can be performed easily under local
anesthesia; (2) the possibility of target geographical miss
is reduced; (3) radiation dose to the surrounding tissues
is minimized due to the sharp dose fall-off outside the
implanted volume, thereby lowering the morbidity; and
(4) it has a shorter treatment time than re-irradiation or
surgery combined with HDR. Krempien et al have
reported that frameless image-guided interstitial needle
implantation was feasible and accurate for 14 patients
with locally recurrent head and neck cancers [42]. The
1- and 2-year local control rates were 78% and 57%,
respectively, and the actuarial 1- and 2-year survival
rates were 83% and 64%, respectively. Image guidance
allows virtual planning and navigated needle implanta-
tion, which, in turn, facilitates optimized dose distribu-
tion and reduces adjacent tissue damage.
We elaborated this technique for routine use in a
large number of recurrent cancer patients by using CT-
guidance and routinely obtained a standard postopera-
tive dosimetry for all patients using the 3D-CT dataset.
This demonstrated that a good tumor control rate and
low complication rate could be achieved using percuta-
neous CT-guided 125I seed permanent implantation
while treating recurrent carcinomas [14,15]. Our results
showed that the 1-, 2-, 3-, and 5-year control rates were
52%, 39%, 39%, and 39%, respectively, with a median
local control of 18 months. The 1-, 2-, 3-, and 5-year
actuarial overall survival rates were 65%, 39%, 39%, and
39%, respectively, with a median survival of 20 months.
In conclusion, CT-guided 125I seed permanent implan-
tation is an effective salvage modality of radiotherapy for
recurrent head and neck carcinoma after previous sur-
gery or EBRT. It eliminates the need for further surgery
or EBRT, improves the outcome, and low side effects.
Considering the limited number of patients involved in
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this study, arriving at a definite conclusion requires a
large number of patients and long-term follow-up.
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